Table 4. Open in new tab Results From...

Table 4.

Results From Linear Mixed Model: 3-Month vs 6-Month Doses

BTM	Doses	Time	Mean	95% CI	Significance
ALP	3-mo	T1	270.7	163 –378	0.007
		T2	173.5	66 –281
		T3	118.5	11 –226
	6–mo	T1	202.5	95 –310
		T2	116.7	6 –228
		T3	177.3	70–285
P1NP	3-mo	T1	450.3	144 –757	0.025
		T2	319.7	13 –626
		T3	91.4	−222–404
	6–mo	T1	319.7	13–626
		T2	175.1	−149 –499
		T3	342.7	36 –649
CTX	3-mo	T1	484	238 –731	0.162
		T2	555	308– 801
		T3	375	106 –643
	6-mo	T1	339	93– 586
		T2	129	−170 –428
		T3	431	185– 678

BTM	Doses	Time	Mean	95% CI	Significance
ALP	3-mo	T1	270.7	163 –378	0.007
		T2	173.5	66 –281
		T3	118.5	11 –226
	6–mo	T1	202.5	95 –310
		T2	116.7	6 –228
		T3	177.3	70–285
P1NP	3-mo	T1	450.3	144 –757	0.025
		T2	319.7	13 –626
		T3	91.4	−222–404
	6–mo	T1	319.7	13–626
		T2	175.1	−149 –499
		T3	342.7	36 –649
CTX	3-mo	T1	484	238 –731	0.162
		T2	555	308– 801
		T3	375	106 –643
	6-mo	T1	339	93– 586
		T2	129	−170 –428
		T3	431	185– 678

A statistically significant difference over time for ALP and P1NP between patients who received denosumab at 3-mo intervals compared with those with 6-mo intervals is shown.

Reference ranges: ALP 40–98 IU/L, P1NP <59 ng/mL, CTX <573 pg/mL.

This Feature Is Available To Subscribers Only